|
Carcinoma of bladder
|
0.040 |
Biomarker
|
disease |
BEFREE |
CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer.
|
15034568 |
2004 |
|
Diminished ovarian reserve
|
0.030 |
Biomarker
|
disease |
BEFREE |
AFC: antral follicle count; BMI: body mass index; DOR: diminished ovarian reserve; E2: estradiol; FPS: follicular-phase stimulation; FSH: follicle stimulating hormone; GnRH: gonadotropin-releasing hormone; HCG: human chorionic gonadotropin; IRB: institutional review board; IVF: in vitro fertilization; LH: luteinizing hormone; LPS: luteal-phase stimulation; MII: metaphase II.
|
29564925 |
2018 |
|
Diminished ovarian reserve
|
0.030 |
Biomarker
|
disease |
BEFREE |
Fragile X premutations are associated with primary ovarian insufficiency when the patient presents with amenorrhea, but the fragile X mental retardation 1 (FMR1) CGG repeat count among cycling women with low ovarian reserve (diminished ovarian reserve [DOR]) is not yet established.
|
22581803 |
2012 |
|
Diminished ovarian reserve
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
This was a cross-sectional survey of women with elevated follicle stimulating hormone levels with (premature ovarian failure or early menopause [POF/EM], n = 20) or without (diminished ovarian reserve [DOR], n = 20) amenorrhea.Seventy-five percent participated.
|
16522406 |
2006 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
When DOR gene expression was silenced or inhibited, the proliferation of HCC cells was inhibited, and tumor cells underwent apoptosis, the cell cycle was arrested and tumor cell invasion and migration were significantly decreased.
|
23903826 |
2013 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, we report that the consequences of altered TP53INP2 splicing on invasion are likely mediated via alterations in Golgi complex integrity during migration on three-dimensional matrices.
|
19934309 |
2009 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
When test results for BMP3 and NDRG4 were combined, the DOR of CRC detection was 98.36, which was higher than that for BMP3 and NDRG4 separately.
|
31097151 |
2020 |
|
Kidney Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Decreased expression of TP53INP2, and increased expression of BCL2A1, IL-6, IL8 and other proinflammatory cytokines were shown in biopsies with BKV nephropathy.
|
31410940 |
2019 |
|
Inflammatory pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation.
|
30690004 |
2019 |
|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Besides, NDRG4 could be also considered as a significant diagnostic marker gene in CRC (DOR: 24.37; 95%CI, 10.11-58.73) and VIM in adenoma (DOR: 15.21; 95%CI, 2.72-85.10).
|
30024936 |
2018 |
|
Constipation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
TAN-452 is a peripherally acting opioid receptor antagonist with selectivity for DOR that attenuates morphine-induced side effects, such as nausea, vomiting, and constipation, without affecting pain control.
|
30036489 |
2018 |
|
Nausea and vomiting
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
TAN-452 is a peripherally acting opioid receptor antagonist with selectivity for DOR that attenuates morphine-induced side effects, such as nausea, vomiting, and constipation, without affecting pain control.
|
30036489 |
2018 |
|
liposarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TP53INP2 expression was required for autophagic activity in liposarcoma cells.
|
28131096 |
2017 |
|
Adult Liposarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TP53INP2 expression was required for autophagic activity in liposarcoma cells.
|
28131096 |
2017 |
|
Childhood Liposarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TP53INP2 expression was required for autophagic activity in liposarcoma cells.
|
28131096 |
2017 |
|
estrogen receptor-negative breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
We conducted a replication study using a dataset outside of the Challenge, and found the association between TP53INP2 and ER-negative breast cancer was significant (p = 5.07x10-3).
|
28957356 |
2017 |
|
melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The present study identified miR-638 as one of the most significantly overexpressed miRNAs in metastatic lesions of melanomas compared with primary melanomas. miR-638 enhanced the tumorigenic properties of melanoma cells in vitro and lung colonization in vivo. mRNA expression profiling identified new candidate genes including TP53INP2 as miR-638 targets, the majority of which are involved in p53 signalling.
|
25650662 |
2015 |
|
Fibromyalgia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We investigated whether skin cytokine and delta opioid receptor (DOR) gene expression in FMS patients differs from controls as one potential contributor to small nerve fiber sensitization.
|
25240423 |
2014 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
On the basis of our previous reports incriminating PIG-U as an oncogene in bladder cancer and PIG-T and GPAA1 as oncogenes in breast cancer, we evaluated the expression pattern of the GPIT subunits in 19 different human cancers at both mRNA and protein levels.
|
18487995 |
2008 |
|
Lymphoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
There was also overexpression of PIG-U and GPI8 in lymphoma.
|
18487995 |
2008 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
On the basis of our previous reports incriminating PIG-U as an oncogene in bladder cancer and PIG-T and GPAA1 as oncogenes in breast cancer, we evaluated the expression pattern of the GPIT subunits in 19 different human cancers at both mRNA and protein levels.
|
18487995 |
2008 |
|
Adult Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
There was also overexpression of PIG-U and GPI8 in lymphoma.
|
18487995 |
2008 |
|
Childhood Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
There was also overexpression of PIG-U and GPI8 in lymphoma.
|
18487995 |
2008 |
|
Ataxia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Our failure to detect causative mutations suggests that alterations in the coding region of TP53INP2 are not responsible for ataxia in this family, although we cannot rule out changes in non-coding elements of this gene.
|
17238154 |
2007 |
|
Cerebellar Ataxia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Our failure to detect causative mutations suggests that alterations in the coding region of TP53INP2 are not responsible for ataxia in this family, although we cannot rule out changes in non-coding elements of this gene.
|
17238154 |
2007 |